![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAXDC2 |
Gene summary for FAXDC2 |
![]() |
Gene information | Species | Human | Gene symbol | FAXDC2 | Gene ID | 10826 |
Gene name | fatty acid hydroxylase domain containing 2 | |
Gene Alias | C5orf4 | |
Cytomap | 5q33.2 | |
Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q96IV6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10826 | FAXDC2 | Dong_P3 | Human | Prostate | Tumor | 8.96e-06 | 1.21e-01 | 0.0278 |
10826 | FAXDC2 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.50e-08 | 5.04e-01 | 0.1633 |
10826 | FAXDC2 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 4.19e-15 | 6.33e-01 | 0.1608 |
10826 | FAXDC2 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 7.25e-09 | 5.64e-01 | 0.1604 |
10826 | FAXDC2 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 2.76e-04 | 4.02e-01 | 0.1602 |
10826 | FAXDC2 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 5.17e-03 | 4.98e-01 | 0.1608 |
10826 | FAXDC2 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 2.32e-02 | 5.02e-01 | 0.1622 |
10826 | FAXDC2 | GSM5353247_PA_PR5269_3_S27_L002 | Human | Prostate | Tumor | 2.39e-02 | 6.22e-01 | 0.1532 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003009919 | Prostate | Tumor | myeloid cell differentiation | 120/3246 | 381/18723 | 6.96e-12 | 5.62e-10 | 120 |
GO:004563719 | Prostate | Tumor | regulation of myeloid cell differentiation | 67/3246 | 210/18723 | 1.71e-07 | 4.25e-06 | 67 |
GO:190370617 | Prostate | Tumor | regulation of hemopoiesis | 103/3246 | 367/18723 | 1.78e-07 | 4.38e-06 | 103 |
GO:004563915 | Prostate | Tumor | positive regulation of myeloid cell differentiation | 35/3246 | 103/18723 | 3.29e-05 | 3.88e-04 | 35 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAXDC2 | SNV | Missense_Mutation | novel | c.884N>G | p.His295Arg | p.H295R | Q96IV6 | protein_coding | tolerated(1) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FAXDC2 | insertion | Nonsense_Mutation | novel | c.298_299insAAGTGGGTCCCACTGTTCCCTGAGTCTGGCTCGCCTTTTCC | p.Val100GlufsTer8 | p.V100Efs*8 | Q96IV6 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
FAXDC2 | insertion | Nonsense_Mutation | novel | c.578_579insGTATTTTTAGTAGGACAGGTTTTCACCATGTTGGTCAGGCTGG | p.His194TyrfsTer3 | p.H194Yfs*3 | Q96IV6 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
FAXDC2 | deletion | Frame_Shift_Del | novel | c.846delN | p.Lys282AsnfsTer124 | p.K282Nfs*124 | Q96IV6 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
FAXDC2 | SNV | Missense_Mutation | novel | c.700N>G | p.Ile234Val | p.I234V | Q96IV6 | protein_coding | tolerated(0.76) | benign(0.001) | TCGA-VS-A8EC-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
FAXDC2 | SNV | Missense_Mutation | novel | c.527N>T | p.Ala176Val | p.A176V | Q96IV6 | protein_coding | tolerated(0.37) | benign(0.007) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
FAXDC2 | SNV | Missense_Mutation | rs748240055 | c.341G>A | p.Arg114Gln | p.R114Q | Q96IV6 | protein_coding | deleterious(0.04) | benign(0.087) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FAXDC2 | SNV | Missense_Mutation | rs763500956 | c.367N>A | p.Val123Met | p.V123M | Q96IV6 | protein_coding | deleterious(0.04) | possibly_damaging(0.749) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FAXDC2 | SNV | Missense_Mutation | novel | c.403G>A | p.Val135Ile | p.V135I | Q96IV6 | protein_coding | deleterious(0.04) | benign(0.115) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FAXDC2 | SNV | Missense_Mutation | rs755057180 | c.643N>A | p.Val215Met | p.V215M | Q96IV6 | protein_coding | deleterious(0) | benign(0.42) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |